Zhong Zheng Wang·2025-12-26 12:41Group 1 - The core point of the article is that Baiyunshan has received approval for the production of a freeze-dried human rabies vaccine (Vero cells), which will enhance the company's product portfolio and competitiveness in the vaccine market [1][2] - Baiyunshan Biological has been focused on the research, production, and sales of vaccines, and has established a research center for the freeze-dried human rabies vaccine [1] - The approval of the rabies vaccine is expected to provide new options for rabies prevention, especially as the pet economy in China is rapidly developing and the demand for human rabies vaccines remains strong [1] Group 2 - Baiyunshan Biological is a key member of the Guangzhou Pharmaceutical Group's biopharmaceutical sector, and the approval of the rabies vaccine is seen as a significant growth point for the group [2] - This approval marks a major breakthrough for Guangzhou Pharmaceutical Group in the industrialization of vaccines and further completes its full industry chain layout from traditional Chinese medicine to chemical drugs and biopharmaceuticals [2] - Baiyunshan Biological plans to focus on the vaccine field, steadily advance market layout, increase R&D investment, and actively pursue the development and technological upgrade of new vaccines [2]